Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
最近の投稿
- 1
Brazil approves law strengthening protective measures for female victims of gender-based violence - 2Cocoa Prices Sink on Favorable Crop Conditions in West Africa
- 3Cyprus: War-related tourism concerns and climate change efforts
- 4Opening Your True capacity: 12 Techniques for Personal growth
- 5Canada Awards C$1.5 Billion Defense Contracts to L3Harris, Airbus
- Putin, Netanyahu discuss Middle East in phone call, Kremlin says
- KJ Apa stars as Jimmy Stewart in new biopic: See his transformation
- Man triggers smoke bomb during failed crypto robbery
- Study reveals how fast weight returns after ending GLP-1 drugs
- Opening Achievement: 8 Methodologies for Compelling Using time productively
- New findings suggest atmosphere could exist on exoplanet TOI-561b
- No injuries after blast at pro-Israel centre in the Netherlands
- Authentic Urban areas: Rich Legacy and Lively Societies
- Some are walking out. Some are shouting. Some are oblivious. How kids are reacting to THAT 'Wicked: For Good' scene
